All those observations of hypoxic-driven chemoresistance in lung cancer are supported by preclinical reports and identified different actors, including direct involvement of HIF-1α, p53 mutation [261,262], CSC [263], YTHDF1 (YTH N6-methyladenosine RNA binding protein 1) [264], miR-128, and miR-155 [148]. This evidence concerns the gene YTHDF1 and lung cancer.